Skip to content

Study to Assess the Effect of Intrauterine Adminstration of HCG Versus Endometrial Injury by Pipelle

An Open-label Prospective Controlled Study to Assess the Effect of Intrauterine Adminstration of HCG Versus Endometrial Injury by Pipelle on the Ongoing Pregnancy Rate in Patients with Unexplained Infertility Undergoing Ovulation Induction

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05050747
Enrollment
402
Registered
2021-09-21
Start date
2021-09-27
Completion date
2024-11-12
Last updated
2025-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female Infertility

Brief summary

Our study aims to describe the effect of the intrauterine adminstration of HCG versus the endometrial injury by pipelle on the ongoing pregnancy rate and the biochemical pregnancy rate in women with unexplained infertility undergoing ovulation induction. Also to describe the effect on the first trimester miscarriage rate, ectopic pregnancy rate, and multiple pregnancy.This study is an open-label, prospective, controlled study, multi-center study. The study participants' relevant medical records will be collected and reviewed after obtaining informed consent for the participants. The study materials that will be used will include blood tests, and ultrasound. The study will involve three study arms.

Detailed description

Our study aims to describe the effect of the intrauterine adminstration of HCG versus the endometrial injury by pipelle on the ongoing pregnancy rate and the biochemical pregnancy rate in women with unexplained infertility undergoing ovulation induction. Also to describe the effect on the first trimester miscarriage rate, ectopic pregnancy rate, and multiple pregnancy.This study is an open-label, prospective, controlled study, multi-center study. The study participants' relevant medical records will be collected and reviewed after obtaining informed consent for the participants. The study materials that will be used will include blood tests, and ultrasound. The study will involve three study arms: Arm 1: Women with unexplained infertility undergoing ovulation induction following intrauterine adminstration of HCG on the day of trigger Arm 2: Women with unexplained infertility undergoing ovulation induction following endometrial injury by pipelle on day 8-9 of the same cycle of ovulation induction Arm 3: Women with unexplained infertility undergoing ovulation induction following intrauterine adminstration of placebo on the day of trigger Primary and secondary key measurements will be used in the study. The primary measures will include: * Signs of ongoing pregnancy Presence of intrauterine gestational sac at 12 weeks Presence of fetal heart pulsation at 12 weeks * Two serum β-HCG levels in 48hrs interval to emphasis biochemical pregnancy The secondary key measures will include: * Occurance of abortion in the 1st trimester * Appearance of ectopic pregnancy diagnosis by: Ultrasound Serum β-HCG level Symptoms of pain and bleeding * Signs of multiple pregnancy Number of intrauterine gestational sacs Number of fetal poles Number of fetal heart pulsations * Recording the the baseline characteristics of the study participants

Interventions

DRUGHCG is introduced at day of trigger intra-uterine

hcg is introduced

DEVICEendometrial injury by pipelle

endometrial injury using pipelle on day 8-9 on the same cycle of ovulation

Sponsors

National Research Centre, Egypt
CollaboratorOTHER
Wael Elbanna Clinic
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
25 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

1. Women with primary or secondary infertility due to unexplained infertility 2. The age group of these women was 25-35 years 3. BMI 18.5-29.9 kg/m2 4. Normal hormone profile (FSH \<10 mIU/ml on day 2-3 and AMH more than 1) 5. Euthyroid state or controlled thyroid state 6. Bilateral free spill on HSG

Exclusion criteria

1. Patients with severe male factor infertility; serum analysis count \< 10 million sperms /mL - sperm motility\<15% - 96%\<abnormal morphology) 2. Stage III or IV endometriosis 3. Bilateral tubal factor infertility 4. Premature ovarian failure 5. Polycystic ovary syndrome 6. Uterine cavity abnormality 7. Recurrent spontaneous abortion

Design outcomes

Primary

MeasureTime frameDescription
Signs of ongoing pregnancyTill the end of the 1st trimesterRecording the following for the three arms of the study: * Signs of ongoing pregnancy Presence of intrauterine gestational sac at 12 weeks Presence of fetal heart pulsation at 12 weeks * Two serum β-HCG levels in 48hrs interval to emphasis biochemical pregnancy

Secondary

MeasureTime frameDescription
occurance of abortion or ectopic or multiple pregnancyTill the end of the 1st trimesterRecording the following for the three arms of the study: * Occurance of abortion in the 1st trimester * Appearance of ectopic pregnancy diagnosis by: Ultrasound Serum β-HCG level Symptoms of pain and bleeding \- Signs of multiple pregnancy Number of intrauterine gestational sacs Number of fetal poles Number of fetal heart pulsations
Recording the baseline characteristics of the study participantsBefore study interventionage , height , weight , body mass index

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026